Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Recruiting now · Phase 2
Conditions studied: Pancreatic Ductal Adenocarcinoma
In brief
A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX and GnP has better efficacy compared to historical observation.
Key facts
- Study ID
- NCT07163273
- Run by
- Northwell Health
- People needed
- 41
- Starts
- 2025-06-20
- Expected to finish
- 2027-06-20
- Last updated by the study team
- 2026-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Imbert Cancer Center — Bay Shore, New York, United States (enrolling)
- Northern Westchester Cancer Center — Mount Kisco, New York, United States (enrolling)
- Long Island Jewish Medical Center — New Hyde Park, New York, United States (enrolling)
- Zuckerberg Cancer Center — New Hyde Park, New York, United States (enrolling)
- Manhattan Eye, Ear and Throat Hospital — New York, New York, United States (enrolling)
- NHPP Medical Oncology at Rego Park — Rego Park, New York, United States (enrolling)
- Phelps Cancer Center — Sleepy Hollow, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.